CombinatoRx formed a research and development agreement with Angiotech. Angiotech will gain access to CombinatoRx’s portfolio of clinical and preclinical products and Chalice™ database of drug combinations. The companies will also form a 5-year research collaboration to identify drug combinations for targets selected by Angiotech.